Guangzhou Kingmed Diagnostics Group Future Growth
Future criteria checks 3/6
Guangzhou Kingmed Diagnostics Group is forecast to grow earnings and revenue by 44.9% and 10.4% per annum respectively. EPS is expected to grow by 45.2% per annum. Return on equity is forecast to be 8.7% in 3 years.
Key information
44.9%
Earnings growth rate
45.2%
EPS growth rate
| Healthcare earnings growth | 23.0% |
| Revenue growth rate | 10.4% |
| Future return on equity | 8.7% |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 06
Earnings Tell The Story For Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)
Sep 27Guangzhou Kingmed Diagnostics Group Co., Ltd. Just Missed Revenue By 9.5%: Here's What Analysts Think Will Happen Next
Sep 03Is Guangzhou Kingmed Diagnostics Group (SHSE:603882) Using Too Much Debt?
Aug 25A Look At The Fair Value Of Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)
Jun 04Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Shareholders Have More To Worry About Than Only Soft Earnings
May 02Investors Don't See Light At End Of Guangzhou Kingmed Diagnostics Group Co., Ltd.'s (SHSE:603882) Tunnel And Push Stock Down 26%
Apr 17Investor Optimism Abounds Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) But Growth Is Lacking
Feb 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 10,040 | 943 | 1,115 | 1,507 | 12 |
| 12/31/2025 | 8,859 | 694 | 372 | 1,610 | 13 |
| 12/31/2024 | 7,609 | 239 | 455 | 1,735 | 9 |
| 9/30/2024 | 7,849 | 161 | 532 | 1,035 | N/A |
| 6/30/2024 | 8,251 | 448 | 279 | 911 | N/A |
| 3/31/2024 | 8,263 | 475 | 195 | 873 | N/A |
| 12/31/2023 | 8,540 | 643 | 516 | 1,231 | N/A |
| 9/30/2023 | 9,578 | 882 | 342 | 1,126 | N/A |
| 6/30/2023 | 11,052 | 1,397 | 729 | 1,448 | N/A |
| 3/31/2023 | 13,342 | 2,054 | 1,325 | 2,077 | N/A |
| 12/31/2022 | 15,476 | 2,755 | 1,107 | 1,948 | N/A |
| 9/30/2022 | 15,534 | 2,996 | 1,463 | 2,352 | N/A |
| 6/30/2022 | 14,800 | 2,803 | 1,349 | 2,325 | N/A |
| 3/31/2022 | 13,516 | 2,532 | 1,018 | 2,018 | N/A |
| 12/31/2021 | 11,943 | 2,220 | 1,136 | 2,088 | N/A |
| 9/30/2021 | 11,034 | 2,127 | 787 | 1,646 | N/A |
| 6/30/2021 | 10,225 | 2,013 | 1,176 | 1,900 | N/A |
| 3/31/2021 | 9,752 | 2,000 | 1,176 | 1,802 | N/A |
| 12/31/2020 | 8,244 | 1,510 | 972 | 1,523 | N/A |
| 9/30/2020 | 7,176 | 1,138 | 807 | 1,240 | N/A |
| 6/30/2020 | 6,201 | 787 | 383 | 745 | N/A |
| 3/31/2020 | 5,276 | 408 | 236 | 555 | N/A |
| 12/31/2019 | 5,269 | 402 | 386 | 661 | N/A |
| 9/30/2019 | 5,128 | 388 | 323 | 635 | N/A |
| 6/30/2019 | 4,954 | 309 | 254 | 571 | N/A |
| 3/31/2019 | 4,771 | 266 | 226 | 558 | N/A |
| 12/31/2018 | 4,525 | 233 | 183 | 530 | N/A |
| 9/30/2018 | 4,309 | 205 | 51 | 384 | N/A |
| 6/30/2018 | 4,107 | 200 | N/A | 340 | N/A |
| 3/31/2018 | 3,909 | 191 | N/A | 289 | N/A |
| 12/31/2017 | 3,792 | 189 | N/A | 284 | N/A |
| 9/30/2017 | 3,689 | 198 | N/A | 292 | N/A |
| 12/31/2016 | 3,222 | 170 | N/A | 292 | N/A |
| 9/30/2016 | 3,010 | 153 | N/A | 253 | N/A |
| 12/31/2015 | 2,389 | 140 | N/A | 220 | N/A |
| 12/31/2014 | 1,838 | 71 | N/A | 226 | N/A |
| 12/31/2013 | 1,356 | 52 | N/A | 76 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603882's forecast earnings growth (44.9% per year) is above the savings rate (2.8%).
Earnings vs Market: 603882's earnings (44.9% per year) are forecast to grow faster than the CN market (26.2% per year).
High Growth Earnings: 603882's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603882's revenue (10.4% per year) is forecast to grow slower than the CN market (13.8% per year).
High Growth Revenue: 603882's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603882's Return on Equity is forecast to be low in 3 years time (8.7%).